Sign in
Taking peopleNo phase

Statins for Treatment of Primary Intracerebral Hemorrhage

Key facts

Who runs it
The Second Hospital of Anhui Medical University
Where
China22 sites in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
264 people, planned
Started
6 May 2023
Expected to end
31 Dec 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Atorvastatin Treatment
  • Best Medical Treatment
Record updated
28 July 2025

Who can take part

Age
18 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Patients with a diagnosis of spontaneous intracerebral hemorrhage (ICH) confirmed by computed tomography (CT)
  • Age 18-80 years
  • Hematoma located in the supratentorial region
  • Time from symptom onset or last known well to baseline CT ranging from 3 to 24 hours
  • Atorvastatin treatment can be initiated within 48 hours of symptom onset or last known well
  • Glasgow Coma Scale (GCS) score ≥9
  • Baseline hematoma volume of 5-35 mL
  • Signed informed consent obtained

Who cannot take part

  • Patients who have undergone or are scheduled for immediate surgical intervention
  • Use of oral anticoagulants within 1 month prior to symptom onset
  • ICH secondary to trauma, tumor, aneurysm, arteriovenous malformation (AVM), vascular anomaly, hemorrhagic transformation of infarction, cerebral venous thrombosis, or anticoagulant-related ICH
  • Pre-stroke mRS >1
  • Known allergy to statins, active liver disease, liver dysfunction, or rhabdomyolysis
  • Known terminal illness with a pre-stroke life expectancy of less than three months, or patients with planned withdrawal of care
  • Pregnancy or lactation

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 80 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The STOP ICH trial is a multicenter, prospective, randomized, open-label, blinded end-point (PROBE) study designed to assess the efficacy and safety of atorvastatin in patients with intracerebral hemorrhage (ICH) presenting within 3 to 24 hours of symptom onset.

The 2 groups in the trial

  • Atorvastatin Treatment plus Best Medical TreatmentTreatment being tested

    Patients in this group will receive atorvastatin treatment plus best medical treatment.

    Treatment: Atorvastatin Treatment and Best Medical Treatment

  • Best Medical TreatmentExisting treatment, for comparison

    Patients in this group will receive best medical treatments in accordance with the guideline-directed management for ICH.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Statins for Treatment Of Primary IntraCerebral Hemorrhage (STOP ICH)
Criteria questions
Built from NCT07088250, who can take part
Record updated
28 July 2025